BriaCell Abstracts Showcase Positive Survival and Clinical Benefit Data at ASCO 2025

Core Insights - BriaCell Therapeutics Corp. announced positive survival and clinical benefit data from its Phase 2 Bria-IMT™ study, which outperformed FDA-approved therapies in metastatic breast cancer patients [1][2][6] - The company will present these findings at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting [1] Clinical Data Summary - The Phase 2 study showed a median overall survival (OS) of 9.9 months and a progression-free survival (PFS) of 3.6 months for the overall cohort, with a clinical benefit rate (CBR) of 55% and an objective response rate (ORR) of 10% [5][9] - In the ongoing pivotal Phase 3 study, the selected formulation of Bria-IMT demonstrated improved OS of 13.4 months and PFS of 3.6 months, with a CBR of 61% and an ORR of 14% [5][8][10] - These results were achieved in a more heavily pre-treated patient population compared to comparator trials, highlighting Bria-IMT's strong anti-cancer activity [10] Comparative Analysis - Bria-IMT's outcomes were compared to two pivotal Phase 3 studies: ASCENT and TROPiCS-02, where ASCENT reported an OS of 11.8 months and TROPiCS-02 reported 14.4 months [7][8] - The CBR for Bria-IMT (61%) exceeded that of ASCENT (40%) and TROPiCS-02 (34%), while the ORR of 14% matched or exceeded the treatment of physician's choice (TPC) arms in both studies [9][10] Future Outlook - Successful completion of the pivotal Phase 3 study may support a Biologics License Application, Priority Review, Full Approval, and Commercialization of Bria-IMT [6][10] - The company is optimistic about confirming results in the ongoing pivotal Phase 3 study and addressing unmet needs in metastatic breast cancer [2][10]